PBLA

Panbela Therapeutics, Inc.

1.26 USD
-0.01 (-0.79%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Panbela Therapeutics, Inc. stock is up 7.69% since 30 days ago. The next earnings date is Mar 14, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 44.44% of the previous 8 March’s closed higher than February. 100% of analysts rate it a buy.

About Panbela Therapeutics, Inc.

Panbela Therapeutics, Inc. focuses on developing disruptive therapeutics for the treatment of patients with cancer. Its lead product candidate is SBP-101, which is in Phase Ia/Ib clinical trial for metastatic pancreatic ductal adenocarcinoma.